Companies /Healthcare

Gilead Sciences Inc

NASDAQ: GILD Drug Manufacturers - General
$156.19
▼ $1.18 (−0.75%) today
Markets closed · 3:28pm ET

24/7 Wall St. View

Price Prediction $188.14 +20.5% Our analysts’ 12-month view: target, optimistic case, and floor. GILD price prediction → Earnings Beat +6.9% EPS vs. the estimate, revenue, and how the market reacted. GILD earnings history →

GILD at a Glance

Valuation
Market cap
$193.7B
Dividend yield
2.05%
Profitability
Revenue (TTM)
$30.5B
Profit margin
-10.6%
EPS (TTM)
$-2.65
Price
52-week range
$111 – $161
24/7 target
$188.14
Street target
$159.85
Earnings
Next report
Oct 29, 2026
Q2 2026 EPS
$-6.75
vs. $-7.25 est.
+6.9%

Headquartered in Foster City, CA Fiscal year ends December NASDAQ: GILD gilead.com

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines to prevent and treat life-threatening diseases. Its primary therapeutic areas include HIV, viral hepatitis, COVID-19, oncology (including cell therapy and antibody-drug conjugates), and inflammation. The company's largest revenue contributor is its HIV portfolio, anchored by Biktarvy and Descovy, with rapid growth in lenacapavir-based products (Yeztugo/Sunlenca) for both treatment and pre-exposure prophylaxis. In oncology, Gilead markets Trodelvy (an antibody-drug conjugate for breast and other cancers), Yescarta and Tecartus (CAR T-cell therapies), and is expanding its pipeline through acquisitions including Arcellx (next-generation CAR T), Tubulis (antibody-drug conjugate platform), and Ouro Medicines (T cell engager for autoimmune diseases). Its liver disease portfolio includes Livdelzi for primary biliary cholangitis, Vemlidy and sofosbuvir/velpatasvir-based products for hepatitis B and C, and Hepcludex for hepatitis delta. Gilead operates in more than 35 countries worldwide. Updated

Latest Activity

GILDGilead Sciences
New 52-week high$153.54+0.3% vs prior high · 2026-02-11

Gilead cleared its February peak with a $153.54 close, its first 52-week high in eight months. Eight months of chop resolved to the upside.

Read more
Biggest dividend payouts · Sep 15
GILDGilead Sciences
$1B$0.82 per share
  • 2XELXcel Energy$0.59/sh$370M
  • 3ARCCAres Capital$0.48/sh$345M
  • 4TROWT. Rowe Price$1.30/sh$277M
  • 5VLYPPValley National Bancorp$0.50/sh$166M

Gilead is sending shareholders about $1.02 billion in cash, 82 cents a share, landing September 29 and dwarfing every other payment today. Xcel Energy, Ares Capital, T. Rowe Price and Valley National Bancorp round out the biggest checks.

Read more

GILD Coverage

Load More

Frequently Asked Questions

What does Gilead Sciences do?

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines to prevent and treat life-threatening diseases. Its primary therapeutic areas include HIV, viral hepatitis, COVID-19, oncology (including cell therapy and antibody-drug conjugates), and inflammation.

What is the GILD stock price target?

24/7 Wall St.'s 12-month price target for GILD is $188.14, rated Buy. The Wall Street consensus target is $159.85. GILD price prediction →